GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Long-Term Capital Lease Obligation

Ocugen (FRA:2H51) Long-Term Capital Lease Obligation : €3.27 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Long-Term Capital Lease Obligation?

Ocugen's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €3.27 Mil.

Ocugen's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 (€3.05 Mil) to Sep. 2023 (€2.97 Mil) but then increased from Sep. 2023 (€2.97 Mil) to Dec. 2023 (€3.27 Mil).

Ocugen's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (€1.09 Mil) to Dec. 2022 (€3.39 Mil) but then declined from Dec. 2022 (€3.39 Mil) to Dec. 2023 (€3.27 Mil).


Ocugen Long-Term Capital Lease Obligation Historical Data

The historical data trend for Ocugen's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Long-Term Capital Lease Obligation Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.32 1.09 3.39 3.27

Ocugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.39 3.22 3.05 2.97 3.27

Ocugen  (FRA:2H51) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Ocugen Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Ocugen's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen (FRA:2H51) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (FRA:2H51) » Definitions » Long-Term Capital Lease Obligation
Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Ocugen (FRA:2H51) Headlines

No Headlines